Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase NA 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 3Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 8Sarcoma 5Lung Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms 4Lymphoma 4Hodgkin Disease 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Rectal Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Adenocarcinoma, Follicular 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Pleural Effusion, Malignant 2Neuroendocrine Tumors 2Mesothelioma 2Melanoma 2Lymphoma, B-Cell 2Liver Neoplasms 2Kidney Neoplasms 2Colonic Neoplasms 2

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Fluorodeoxyglucose F18 × Clear all
NCT01697527 2025-11-24

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Jonsson Comprehensive Cancer Center

Phase 2 Active not recruiting
6 enrolled
Tumor-Agnostic

Neoplasms

NCT06956391 2025-06-04

Ultralow Dose PET Imaging of 18F-FDG Uptake

Nuclear Imaging Institute

Phase 2 Recruiting
200 enrolled
Tumor-Agnostic

Neoplasms

NCT00375830 2023-12-12

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Stanford University

Phase 2 Completed
114 enrolled 19 charts
Tumor-Agnostic

Neoplasms

NCT00001568 2008-03-04

Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
200 enrolled
Gastrointestinal

Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡